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progression or cardiovascular outcomes in
dialysis patients without previous
cardiovascular disease
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There are errors in the “Hemoglobin (mmol/L)” values in Table 1, Table 2 and Table 3. Please
see the corrected tables here.
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Table 1. Main Baseline characteristics according to dialysis modality.
PDa patients HDb patients p
(n = 237) (n = 237)
Males (%) 137 (58) 146 (61.8) 0.45
Age (years) 52 [42;63] 55 [43;63] 0.11
Smoker (former/current) (%) 135 (57) 137 (58) 0.92
Diabetes (%) 43 (18.1) 43 (18.1) 1
Hypertension (%) 219 (92.4) 199 (84) 0.007
Dyslipidemia (%) 153 (64.6) 123 (47.7) <0.001
Etiology of renal disease (%): 0.670
Diabetic nephropathy 25 (10.5) 27 (11.4)
Vascular disease 23 (9.7) 29 (12.2)
Others 189 (79.7) 181 (76.4)
Dialysis time (months) 13.7 [6.2;28.9] 14.3 [6.41;28.6] 0.91
Body mass index (kg/m2) 26.4 [23.3;29.2] 25.3 [23;28.6] 0.23
Systolic Blood Pressure (mmHg) 140 [129;159] 135 [120;151] 0.001
Diastolic Blood Pressure (mm Hg) 83 [77;94] 80 [70;88] <0.001
Pulse Pressure (mmHg) 56 [45;69] 55 [46;63] 0.53
Serum glucose (mmol/L) 5.05 [2.96;6.10] 5.05 [4.56;6.10] 0.838
Urea (mmol/L) 21.5 [17.6;25.8] 20.8 [15.8;25] 0.07
Creatinine (μmol/L) 682.5 [519.8;884] 727.5 [574.6;884] 0.1
Total colesterol (mmol/L) 4.58 [3.99;5.20] 3.91 [3.37;4.53] <0.001
HDL-cholesterol (mmol/L) 1.22 [1.01;1.48] 1.09 [0.90;1.29] <0.001
LDL-cholesterol (mmol/L) 2.66 [2.07;5.15] 2.07 [1.63;2.64] <0.001
Triglycerides (mmol/L) 1.34 [1.07;1.87] 1.41 [1.03;1.92] 0.75
Serum uric acid (μmol/L) 345.1 [303.4;401.6] 362.9 [321.3;425.4] 0.006
hs C-Reactive Protein (nmol/L) 19 [8.95;49.9] 22.47 [10.09;58.66] 0.23
Albumin (mol/L) 0.59 [0.54;0.62] 0.59 [0.54;0.64] 0.025
Hemoglobin (mmol/L) 7.2 [7.01;8.01] 7.26 [6.70;7.76] <0.001
Corrected calcium (mmol/L) 2.3 [2.20;2.42] 2.26 [2.16;2.36] <0.001
Phosphate (mmol/L) 1.6 [1.35;1.84] 1.54 [1.25;1.79] 0.035
iPTH (pmolL) 22.7 [14.9;35.4] 25.7 [14.3;36.4] 0.23
25-hydroxy-vitamin D (nmol/L) 28.9 [20.9;41.2] 37.4 [26.4;48.7] <0.001
1-25-hydroxy-vitamin D (pmol/L) 13.6 [9.72;19.9] 13.8 [9.31;22.3] 0.54
Treatments
Antihypertensive (%): 214 (90.3) 159 (67.1) <0.001
ACEIc (%) 66 (27.8) 41 (17.3) 0.008
ARBsd (%) 111 (46.8) 54 (22.8) <0.001
Diuretics (%) 128 (54) 45 (19) <0.001
Statins (%) 137 (57.8) 110 (46.4) 0.017
Phosphate binders (%): 198 (83.5) 189 (79.7) 0.343
Binders without Cae (%) 126 (53.2) 138(58.2) 0.309
Binders with Cae (%) 42 (47.2) 40 (47.1) 1
Cae intake (binders) (gr/day) 1.5 [1;2] 1.65 [1;3] 0.027
Calcitriol/Paricalcitol (%) 97 (40.9) 122 (51.5) 0.027
Calcifedol /%)
Cholecalciferol (%) 27 (11.4) 8 (3.38) 0.002
Cinacalcet (%) 11(4.64) 8 (3.38) 0.640
Antiplatelet drugs (%): 27 (24.1) 68 (28.7) 0.297
(Continued)
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Table 1. (Continued)
PDa patients HDb patients p
(n = 237) (n = 237)
ESAf(%) 181(76.4) 198 (83.5) 0.066
Renal transplantation centre (%) 88 (37.1) 62 (26.2) 0.014
Plaque presence (%) 123 (51.9) 143 (60.3) 0.08
Number of territories with plaque 2 [1.0;3.0] 2 [1.0;3.0] 0.285
cIMTg (mm) 0.65 [0.56;0.79] 0.70 [0.6;0.84] 0.009
Ankle-Brachial index (%)
ABI < 0.9 37 (15.7) 23 (9.91) 0.08
ABI >0.9-<1.4 175 (74.5) 144 (62.1) 0.005
ABI > 1.4 23 (9.79) 65 (28) <0.001
Data are presented as median [interquartile range], mean (standard deviation) or n(%).
a Peritoneal dialysis
b Hemodialysis
c Angiotensin converting enzyme inhibitors
d Angiotensin II receptor blockers
e Calcium
f Erythropoiesis stmulating agents
g Common carotid artery intima media thickness
https://doi.org/10.1371/journal.pone.0200226.t001
Table 2. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.
PDa patients HDb patients p
(n = 82) (n = 85)
Males (%) 47 (57.3) 48 (52.2) 0.6
Age (years) 53 [42.5;63] 55 [44.8;64] 0.39
Smoker (former/current) (%) 49 (59.8) 48 (52.2) 0.9
Diabetes (%) 14 (17.1) 14 (15.2) 0.9
Hypertension (%) 75 (91.5) 79 (86) 0.359
Dyslipidemia (%) 58 (70.7) 55 (59.8) 0.176
Etiology of renal disease (%): 0.670
Diabetic nephropathy 7 (8.54) 8 (8.7)
Vascular disease 8 (9.76) 13 (14.1)
Others 67 (81.7) 71 (77.2)
Dialysis time (months) 10.5 [4.46;19.2] 11.5 [5.82;25.8] 0.131
Body mass index (kg/m2) 26.4 [23.3;28.4] 26.1 [23;4.32.2] 0.446
Systolic Blood Pressure (mmHg) 145 (24.4) 138 (21.8) 0.03
Diastolic Blood Pressure (mm Hg) 87.5 (12.2) 78.8 (13.3) <0.001
Pulse Pressure (mmHg) 56 [44;69] 56.5 [47;70.2] 0.579
Serum glucose (mmol/L) 5.16 [4.72;5.61] 5.23 [4.55;6.05] 0.931
Urea (mmol/L) 22.11 (6.76) 20.31 (6.13) 0.053
Creatinine (μmol/L) 596.7 [468.5;792.1] 676.3 [583.4;837.2] 0.815
Total colesterol (mmol/L) 4.75 [4.2;5.43] 3.9 [3.2;4.45] 0.258
HDL-cholesterol (mmol/L) 1.21 [1;1.52] 1.1 [0.88;1.21] 0.005
LDL-cholesterol (mmol/L) 3.46 [2.28;3.05] 3.36 [2.56;4.4] <0.001
(Continued)
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Table 2. (Continued)
PDa patients HDb patients p
(n = 82) (n = 85)
Triglycerides (mmol/L) 1.53 [1.09;2.02] 1.48 [1.13;1.94] 0.940
Serum uric acid (μmol/L) 350.4 (72.6) 369.4 (70.78) 0.093
hs C-Reactive Protein (nmol/L) 26.28 [10;61.24] 24 [10.47;62.48] 0.815
Albumin (mol/L) 0.59 [0.53;0.62] 0.59 [0.54;0.64] 0.471
Hemoglobin (mmol/L) 7.24 (0.80) 6.82 (0.84) 0.002
Corrected calcium (mmol/L) 2.32 [2.22;2.4] 2.25 [2.16;2.32] 0.031
Phosphate (mmol/L) 1.52[1.32;1.81] 1.55 [1.29;1.81] 0.965
iPTH (pmolL) 21.1 [15.48;34.25] 26.51 [16.2;41] 0.182
25-hydroxy-vitamin D (nmol/L) 30.5 [21.75;43.75] 35.5 [27;48] 0.014
1-25-hydroxy-vitamin D (pmol/L) 15.45 [10.3;22.7] 14.4 [10.15;25.75] 0.862
Treatments
Antihypertensive (%): 72 (87.8) 60 (65.2) 0.001
ACEIc (%) 20 (24.4) 15 (16.3) 0.255
ARBsd (%) 37 (45.1) 25 (27.2) 0.021
Diuretics (%) 27 (32.6) 28 (32.9) 0.837
Statins (%) 48 (58.3) 50 (54.3) 0.687
Phosphate binders (%): 66 (80.5) 68 (73.9) 0.396
Binders without Cae (%) 38 (46.3) 48(52.2) 0.538
Binders with Cae (%) 42 (47.2) 40 (47.1) 1
Cae intake (binders) (gr/day) 1 [1;1.5] 1.5 [1;2.5] 0.03
Calcitriol/Paricalcitol (%) 34 (41.5) 44 (47.8) 0.490
Calcifedol /%) 8 (9.76) 5 (5.43) 0.428
Cholecalciferol (%) 2 (2.44) 4 (4.35) 0.685
Cinacalcet (%) 18 (22) 24 (26.1) 0.646
Antiplatelet drugs (%): 22 (26.8) 27 (29.3) 0.842
ESAf (%) 62 (75.6) 77 (83.7) 0.255
Renal transplantation centre (%) 27 (32.9) 20 (21.7) 0.137
Plaque presence (%) 44 (53.7) 53 (57.6) 0.711
Number of territories with plaque 2 [1.0;2.0] 2 [1.0;3.0] 0.149
cIMTg (mm) 0.65 [0.57;0.75] 0.72 [0.62;0.86] 0.005
Ankle-Brachial index (%) <0.001
ABI <0.9 10 (12.2) 7 (7.78)
ABI >0.9-<1.4 66 (80.5) 55 (61.1)
ABI > 1.4 6 (7.32) 21 (31.1)
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Peritoneal dialysis
b Hemodialysis
c Angiotensin converting enzyme inhibitors
d Angiotensin II receptor blockers
e Calcium
f Erythropoiesis stimulating agents
g Common carotid artery intima media thickness
https://doi.org/10.1371/journal.pone.0200226.t002
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Table 3. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.
AVDa progression Non AVD progression p
(n = 89) (n = 85)
Males (%) 50 (56.2) 45 (52.9) 0.78
Age (years) 57 [48;65] 50 [39;62] 0.004
Smoker (former/current) (%) 53 (59.6) 44 (51.8) 0.38
Diabetes (%) 20 (22.5) 8 (9.41) 0.033
Hypertension (%) 79 (88.8) 75 (88.2) 1
Dyslipidemia (%) 59 (66.3) 54 (63.5) 0.824
Etiology of renal disease (%): 0.165
Diabetic nephropathy 25 (10.5) 27 (11.4)
Vascular disease 23 (9.7) 29 (12.2)
Others 69 (77.5) 69 (81.2)
Dialysis time (months) 10.2 [4.4;23.2] 11.8 [6.47;22.5] 0.27
Body mass index (kg/m2) 27 [23.6;30.7] 26.1 [23.1;28.8] 0.156
Systolic Blood Pressure (mmHg) 142 (24.3) 141 (24.3) 0.735
Diastolic Blood Pressure (mm Hg) 82 (13.5) 83.9 (13.5) 0.343
Pulse Pressure (mmHg) 60 [44;74] 56 [45;66] 0.326
Serum glucose (mmol/L) 5.18 [4.54;6.10] 5.05 [4.49;5.66] 0.157
Urea (mmol/L) 18.3 (5.25) 18.3 (5.21) 0.984
Creatinine (μmol/L) 610 [486.2;797.4] 662.1 [557.8;839.8] 0.089
Total colesterol (mmol/L) 4.14 [3.63;4.89] 4.45 [3.57;5.33] 0.258
HDL-cholesterol (mmol/L) 1.10 [0.93;1.39] 1.16 [0.96;1.37] 0.561
LDL-cholesterol (mmol/L) 2.30 [1.85;2.82] 2.61 [1.81;2.98] 0.264
Triglycerides (mmol/L) 1.51 [1.11;2.10] 1.38 [1.07;1.92] 0.528
Serum uric acid (μmol/L) 370.5 (72.6) 350.4 (70.8) 0.084
hs C-Reactive Protein (nmol/L) 37.7 [13.8;65.9] 18.5 [8.4;54.2] 0.04
Albumin (mol/L) 0.59 [0.0.53;0.63] 0.59 [0.54;0.62] 0.613
Hemoglobin (mmol/L) 7 (0.95) 7 (0.80) 0.962
Corrected calcium (mmol/L) 2.31 [2.19;2.4] 2.26 [2.12;2.37] 0.419
Phosphate (mmol/L) 1.52 [1.26;1.81] 1.55 [1.36;1.84] 0.292
iPTH (pmolL) 24.7 [15.9;38.1] 23.3 [15.27;36.7] 0.586
25-hydroxy-vitamin D (nmol/L) 30.9 [22.8;42.9] 36.4 [26.7;48.7] 0.043
1-25-hydroxy-vitamin D (pmol/L) 14.9 [10.0;24.5] 13.6 [9.7;22.3] 0.602
Treatments
Antihypertensive (%): 68 (76.4) 64 (75.3) 1
ACEIb (%) 18 (20.2) 17 (20) 1
ARBsc (%) 29 (32.6) 33 (38.8) 0.483
Diuretics (%) 27 (32.6) 28 (32.9) 0.837
Statins (%) 51 (57.3) 47 (55.3) 0.9
Phosphate binders (%): 68 (76.4) 66 (77.6) 0.98
Binders without Cad (%) 39 (43.8) 47 (55.3) 0.173
Binders with Cad (%) 42 (47.2) 40 (47.1) 1
Cad intake (binders) (gr/day) 1 [1;1.5] 1.5 [1;2.5]
Calcitriol/Paricalcitol (%) 45 (50.6) 33 (38.8) 0.16
Calcifedol /%) 9 (10.1) 4 (4.71) 0.286
Cholecalciferol (%) 3 (3.37) 3 (3.53) 1
Cinacalcet (%) 19 (21.3) 23 (27.1) 0.482
Antiplatelet drugs (%): 27 (30.3) 22 (25.9) 0.628
(Continued)
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Table 3. (Continued)
AVDa progression Non AVD progression p
(n = 89) (n = 85)
ESAe (%) 66 (74.2) 73 (85.9) 0.082
Renal transplantation centre (%) 22 (24.7) 25 (29.4) 0.599
Plaque at baseline (%) 64 (71.9) 33 (33.8) <0.001
Number of territories with plaque 2 [1.0;3.0] 2 [1.0;3.0] 0.398
cIMTf (mm) 0.73 [0.65;0.89] 0.64 [0.56;0.74] <0.001
Ankle-Brachial index (%)
ABI <0.9 11 (12.5) 6 (7.14) 0.357
ABI >0.9-<1.4 57 (64.8) 64 (76.2) 0.141
ABI > 1.4 20 (22.7) 14 (16.7) 0.420
Dialysis modality: 0.437
Hemodialysis 44 (49.4) 48 (56.5)
Peritoneal dialysis 45 (50.6) 37 (43.5)
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Atheromatous vascular disease
b Angiotensin converting enzyme inhibitors
c Angiotensin II receptor blockers
d Calcium
e Erythropoiesis stimulating agents
f Common carotid artery intima media thickness
https://doi.org/10.1371/journal.pone.0200226.t003
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